Clinical Trial Update: Safety and Efficacy Study of Etanercept (Qiangke®) to Treat Moderate to Severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

This document provides an update on a Phase 3 clinical trial evaluating Etanercept (Qiangke) for safety and efficacy in moderate-to-severe plaque psoriasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis
• Psoriasis

Drugs mentioned

• Qiangke (Etanercept)

Snippet

Sponsor: Shanghai Celgen Bio-Pharmaceutical Co.,Ltd | Conditions: Plaque Psoriasis, Psoriasis | Phase 3 | Status: UNKNOWN